Alkermes Inc., a Waltham biotech focused on treatments for central nervous system disorders, addiction and diabetes, has returned positive results from its Phase 1b study of ALKS 9070, its treatment for schizophrenia.

The once-monthly dosage of ALKS 9070 showed it was “generally well tolerated” and the plasma concentrations of aripiprazole, known commercially as Abilify, which the drug candidate converts to, matched appropriate concentrations for the dosage schedule.

SOURCE